Alkermes Plc  

(Public, NASDAQ:ALKS)   Watch this stock  
Find more results for alks
55.98
-0.10 (-0.18%)
Jan 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 55.14 - 56.32
52 week 27.14 - 60.74
Open 56.06
Vol / Avg. 756,023.00/779,304.00
Mkt cap 8.49B
P/E     -
Div/yield     -
EPS -1.70
Shares 151.97M
Beta 2.12
Inst. own 98%
Feb 23, 2017
Q4 2016 Alkermes Plc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 10, 2017
Alkermes Plc at JPMorgan Healthcare Conference Q&A
Jan 10, 2017
Alkermes Plc at JPMorgan Healthcare Conference
Nov 16, 2016
Alkermes Plc at Jefferies Healthcare Conference - Webcast
Nov 8, 2016
Alkermes Plc at Credit Suisse Healthcare Conference
Nov 2, 2016
Q3 2016 Alkermes Plc Earnings Release
Nov 2, 2016
Q3 2016 Alkermes Plc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -34.78% -36.15%
Operating margin -33.91% -35.70%
EBITD margin - -22.08%
Return on average assets -14.40% -12.04%
Return on average equity -20.50% -16.76%
Employees 1,500 -
CDP Score - -

Address

Connaught HSE, 1 Burlington Road
DUBLIN, MA 00000
Ireland
+353-1-7728000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alkermes Public Limited Company is a biopharmaceutical company. The Company is engaged in researching, developing and commercializing, both with partners and on its own, pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of approximately 20 products and a clinical pipeline of product candidates that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis. Its products include ARISTADA, VIVITROL, RISPERDAL CONSTA, INVEGA SUSTENNA/XEPLION & INVEGA TRINZA, AMPYRA/FAMPYRA, BYDUREON, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, Aripiprazole Lauroxil Two-Month Dose, ALKS 7119 and RDB 1450. Its product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release technology.

Officers and directors

Richard F. Pops Chairman, President, and CEO
James M. (Jim) Frates SVP, CFO, and Treasurer
Gordon G. Pugh SVP, COO, and Chief Risk Officer
Richard F. Pops Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Shane M. Cooke President
Age: 53
Bio & Compensation  - Reuters
James M. Frates Chief Financial Officer, Senior Vice President
Age: 48
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Kathryn L. Biberstein Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Secretary
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Elliot W. Ehrich M.D. Executive Vice President - Research and Development and Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Michael J. Landine Senior Vice President - Corporate Development
Age: 62
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark P. Stejbach Senior Vice President, Chief Commercial Officer
Age: 52
Bio & Compensation  - Reuters